Optometry Times On the Air: Recent Episodes
Optometry Times On the Air
Listen to a variety of podcasts from the Optometry Times® editorial team and key opinion leaders in the industry.
Thanks for your interest in this podcast. Please read this important program information before listening.
Episode Description
In this podcast, retina specialist John Kitchens, MD, has a conversation with a patient about the choice he made for anti-VEGF therapy to reduce his treatment burden, then discusses recent clinical trial data on therapeutic options with extended treatment intervals.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Identify unmet needs and treatment burden associated with conventional therapies for patients with DME and nAMD
- Evaluate recent clinical trials and real-world data on the safety, effectiveness, and durability of the ranibizumab port delivery system and other anti-VEGF therapies for patients with DME and nAMD
- Apply best practices to guide the use of the ranibizumab port delivery system and other anti-VEGF therapies when managing patients with DME and nAMD
Acknowledgment of Educational Grant Support
This activity is supported by an educational grant from Genentech, Inc.
Chair:
John Kitchens, MD
Retina Associates of Kentucky
Eye Care Partners
Disclosures: Advisor, Consultant, Fee for Service Recipient: Alcon, Apellis, Astellas, Bayer, Roche Speakers Bureau: Apellis, Astellas, Bayer, Roche, Regeneron Ownership in Public Traded Companies: Vortex Surgical
Faculty, Staff, and Planners’ Disclosures
In accordance with ACCME Guidelines, PER® has identified and resolved all conflict of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
This podcast, including the narration, was developed by PER® editorial staff based on an online activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool.
To learn more about this topic, including information on educating patients on their anti-VEGF options, go to https://www.gotoper.com/courses/reducing-treatment-burden-in-retinal-disease-care-with-extended-duration-anti-vegf-therapies.
Release Date
June 30, 2026
Expiration Date
June 30, 2027
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
Thanks for your interest in this podcast. Please read this important program information before listening.
Episode Description
In this podcast, experts Francis Mah, MD; and Amy Nau, OD, FAAO, Dipl, CCLRT; discuss how to identify neurotrophic keratitis in practice, highlighting indications for corneal sensitivity testing based on patient history and examination findings. Faculty will also examine how to stage and treat neurotrophic keratitis once diagnosed.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Describe the signs and symptoms that contribute to a diagnosis of neurotrophic keratitis, including reduced or absent corneal sensitivity
- Integrate the Mackie classification system to stage neurotrophic keratitis as part of the comprehensive clinical evaluation
- Summarize recommendations for corneal sensitivity testing based on patient history and clinical findings
Acknowledgment of Educational Grant Support
This activity is supported by an educational grant from Dompé US.
Faculty:
Francis Mah, MD
Director, Cornea Service
Co-Director, Refractive Surgery Service
Scripps Clinic Torrey Pines
La Jolla, CA
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: AbbVie, Alcon, Aperta, Azura, Bausch + Lomb, BioTissue, BVI, ClearSight, Evolve, Eyenovia, EyeYon, Glaukos, Invirsa, iView, Johnson & Johnson Vision, Kala Bio, Lenz Therapeutics, OcuTerra, OSRX, PMN, PolyActiva, Puget Sound Therapeutics, Signal12, Sophia Bio, STAAR, Sydnexis, Tarsus Pharmaceuticals, Viatris, Yuyu Pharma, Zeiss; Ownership Interests in Privately Held Companies: Avellino Group, Eyenovia, Horizon Surgical Systems, iView, Kala Bio, Okogen, OSRX, Puget Sound Therapeutics, Signal12, Sophia Bio, Sydnexis
Amy Nau, OD, FAAO, Dipl, CCLRT
Adjunct Associate Professor
New England College of Optometry
Co-Owner, Forefront Eye Care
Co-Founder/CEO, Eyewell
Boston, MA
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: InMode; Speakers Bureau: Tarsus, Vital Tears; Equity Owner: Eyewell, Forefront Eye Care; Other: Educational Sponsorship: BioTissue, Dompé, Glaukos, InMode, LacriFill, Lumenis, Ocubio, RxSight
Faculty, Staff, and Planners’ Disclosures
In accordance with ACCME Guidelines, PER® has identified and resolved all conflicts of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.
The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies.
This podcast, including the narration, was developed by PER® editorial staff based on a live activity developed with this faculty. The narration was voiced by a PER staff member or by an AI tool.
To learn more about this topic, including clinical trial data of therapies used for neurotrophic keratitis, go to https://www.gotoper.com/courses/searching-for-silence-corneal-sensitivity-testing-in-nk-9b9i.
Release Date
June 15, 2026
Expiration Date
June 15, 2027
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
Thanks for your interest in this podcast. Please read this important program information before listening.
Episode Description
In this podcast, experts Charles C. Wykoff, MD, PhD, FASRS; Jed H. Assam, MD, MS; Diana V. Do, MD; and Dante Pieramici, MD, FASRS; discuss the diagnosis, clinical features, and evolving management strategies for patients diagnosed with macular telangiectasia (MacTel) type 2.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Summarize the limitations of anti-VEGF intravitreal injection therapies in the management of MacTel.
- Evaluate emerging evidence supporting the use of novel therapies in the management of MacTel.
- Integrate current evidence-based interventions for MacTel into clinical practice to optimize disease outcomes.
- Apply advanced diagnostic and therapeutic interventions to the management of MacTel.
Acknowledgment of Educational Grant Support
This activity is supported by an educational grant from Neurotech Pharmaceuticals, Inc.
Faculty:
Charles C. Wykoff, MD, PhD, FASRS
Director of Research, Retina Consultants of Texas
Chairman of Research & Clinical Trials, Retina Consultants of America
Houston, TX
Disclosures: Consultant/Honoraria: 4DMT, AbbVie, Acuta, ADARx, Adverum, Alcon, Alimera, Alkeus, Allgenesis, AMC Sciences, Annexon, Apellis, Arrowhead, Ascidian, Astellas, Aviceda, Bausch + Lomb, Bayer, BioCryst, Bionic Vision, Boehringer Ingelheim, Chengdu Kanghong, Curacle, Emmecell, Eyebiotech, EyePoint, Genentech, InGel, Janssen, Kiora, Kodiak, Kowa, Nanoscope, Neurotech, NGM, Novartis, Oak Bay Bio, Ocular Therapeutix, OcuTerra, Ollin, ONL, Opthea, Opus, Osanni, Oxular, Palatin, Perceive Bio, Perfuse, Ray, Regeneron, Regenxbio, RetinAI, Roche, Samsung Bioepis, Sandoz, Sanofi, Santen, Skyline, Stealth, Sylentis, TCG Crossover, THEA, Therini, VH401,Visgenx, Zeiss; Research Grants: 4DMT, AbbVie, Adverum, AffaMed, Alexion, Alimera, Allgenesis, Amgen, Annexin, Annexon, Apellis, Ascidian, AsclepiX, Astellas, Aviceda, Avirmax, Bayer, Boehringer Ingelheim, Chengdu Origen, Clearside, Curacle, Eluminex, Eyebiotech, EyePoint, Genentech, IONIS, iRenix, Janssen, Kalaris, Kodiak, Kyoto DDD, Kyowa Kirin, Nanoscope, Neurotech, NGM, Novartis, Ocugen, Ocular Therapeutix, Oculis, OcuTerra, OliX, Ollin, Opthea, Outlook Therapeutics, Oxular, Oxurion, Perceive Bio, Pykus, Regeneron, Regenxbio, Rezolute, Roche, Shanghai Henlius, Stealth, Skyline, VH401; Stock Options (Not Owner) From Private For-Profit Entities: InGel, Ollin, ONL, Osanni, Panther, TissueGen, Visgenx, Vitranu
Diana V. Do, MD
Vice Chair of Clinical Affairs
Professor of Ophthalmology
The Byers Eye Institute
Stanford University School of Medicine
Palo Alto, CA
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: Apellis, Astellas, Belite Bio, LumiThera, Oculis, Regenxbio; Grant/Research Funding: Apellis, Belite Bio, LumiThera, Neurotech, Oculis, Regeneron, Regenxbio; Ownership Interests in Publicly-Traded Companies: Belite Bio, Kodiak Sciences
Dante Pieramici, MD, FASRS
Medical Director, Clinical Research, California Retina Consultants
Director, California Retina Research Foundation
Partner, California Retina Consultants/Retina Consultants of America
Santa Barbara, CA
Disclosures: Advisory: Perceive; Consultant: 4DMT, Adverum, Eyepoint, Genentech, Neurotech, Ocular Therapeutix, Opthea, Regeneron, Retina AI, Roche, Samsung, Unity; Research Funding: 4DMT, Adverum, Eyepoint, Genentech, Novartis, Ocular, Ocular Therapeutix, Opthea, Regeneron, Retina AI, Roche; Unity
Jed H. Assam, MD
Clinical Faculty
Department of Surgery
University of South Dakota
Sanford School of Medicine
Sioux Falls, SD
Disclosures: Jed H. Assam, MD, has no relevant financial relationships with ineligible companies.
Faculty, Staff, and Planners’ Disclosures
In accordance with ACCME Guidelines, PER® has identified and resolved all conflicts of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
This podcast, including the narration, was developed by PER® editorial staff based on an online activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool.
To learn more about this topic, including the diagnosis and interdisciplinary management of MacTel, go to https://www.gotoper.com/courses/mactel-decoded-rethinking-conventional-approaches-with-novel-neuroprotective-strategies.
Release Date
January 30, 2026
Expiration Date
January 30, 2027
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
Thanks for your interest in this podcast. Please read this important program information before listening.
Episode Description
In this podcast, experts Janelle L. Davison, OD; Cecelia Koetting, OD, FAAO, DipABO; and Cory J. Lappin, OD, MS, FAAO; discuss neuromodulation as a treatment modality for dry eye disease, focusing on a novel thermoregulatory therapy.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Describe the neural network that monitors the ocular surface environment and regulates tear secretion
- Assess the mechanisms of action of neuromodulation therapeutics in dry eye disease (DED)
- Evaluate current and emerging therapeutics for DED
- Identify clinical applications and patient selection for neuromodulation therapies in DED
Acknowledgment of Educational Grant Support
This activity is supported by an educational grant from Alcon Vision, Inc.
Faculty:
Janelle L. Davison, OD
Owner and Clinical Director
Brilliant Eyes Vision Center
Visionary Dry Eye Institute
Smyrna, GA
Disclosures: Janelle L. Davison, OD, has no relevant financial relationships with ineligible companies.
Cecelia Koetting, OD, FAAO, DipABO
Assistant Professor
Department of Ophthalmology
University of Colorado School of Medicine
Denver, CO
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: AbbVie/Allergan, Alcon Inc, Bausch + Lomb, Dompé, Harrow, Movu, Myze, Orasis Pharmaceuticals, Tarsus Pharmaceuticals, Topcon, Viatris Inc, Visus; Grant/Research Funding: Kala Bio
Cory J. Lappin, OD, MS, FAAO
Founder
The Dry Eye Center of Ohio
Cincinnati, OH
Disclosures: Advisory Board, Consultant, Speaker: Alcon Inc; Barti; Bausch + Lomb; Bruder Healthcare and M&S Technologies (Hilco Vision); CSI Dry Eye Software; Dompé Pharmaceuticals; Eyederm; Eyenovia; Harrow, Inc; Lumenis; Myze; Nordic Pharma; Norwood Device & Diagnostics; NuLids; Ocubio; PRN Vision Group; Rinsada; SCOPE Health Inc; Sight Sciences; Tarsus Pharmaceuticals, Inc; TearRestore Inc; Viatris Inc (Oyster Point Pharma); Vital Tears LLC; Investment: Barti, Myze, NuLids; Ownership Stake: Eyederm; Executive Team Member: Myze; Medical Director: Norwood Device & Diagnostics
Faculty, Staff, and Planners’ Disclosures
In accordance with ACCME Guidelines, PER® has identified and resolved all conflicts of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
This podcast, including the narration, was developed by PER® editorial staff based on an online activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool.
To learn more about this topic, including further data on neuromodulating dry eye therapies, go to https://www.gotoper.com/boston25optometry-ded-activity
Release Date
January 30, 2026
Expiration Date
January 30, 2027
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
Thanks for your interest in this podcast. Please read this important program information before listening.
Episode Description
In this podcast, expert Mile Brujic, OD, FAAO, discusses the burden, diagnosis, and management of Demodex blepharitis, highlighting a recently approved targeted treatment option.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Summarize the disease burden in patients with Demodex blepharitis
- Assess objective and subjective clinical findings to establish a diagnosis of Demodex blepharitis
- Implement targeted therapies in treatment plans to eradicate Demodex and improve outcomes in patients with Demodex blepharitis
Acknowledgment of Educational Grant Support
This activity is supported by an educational grant from Tarsus Pharmaceuticals, Inc.
Chair:
Mile Brujic, OD, FAAO
Premier Vision Group
Bowling Geen, OH
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: ABB Optical Group, AbbVie, Alcon, Apellis, Art Optical, Bausch + Lomb Health, Contamac, CooperVision, CS Eye, Dompé, Dopavision, Glaukos, Iveric Bio, Johnson & Johnson Vision Care, Lentechs, MDelite, Nordic Pharma, Notal Vision, Orasis, Radius XR, RVL, Sun Pharma, Tangible Science, Tarsus, Viatris, Visionix, Walman Optical, ZeaVision
Faculty, Staff, and Planners’ Disclosures
In accordance with ACCME Guidelines, PER® has identified and resolved all conflicts of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.
The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies.
This podcast, including the narration, was developed by PER® editorial staff based on an online activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool.
Release Date
January 31, 2026
Expiration Date
January 31, 2027
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
Episode Description
In this podcast, experts John D. Gelles, OD, FAAO, FIAOMC, FCLSA, FSLS, FBCLA; and John Hovanesian, MD, FACS; discuss the importance of comprehensive strategies when performing corneal sensitivity testing in patients suspected of having neurotrophic keratitis (NK).
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Summarize the importance of a timely and accurate diagnosis of neurotrophic keratitis
- Integrate corneal sensitivity testing into the assessment of ocular surface disease
Acknowledgment of Educational Grant Support
This activity is supported by an educational grant from Dompé US, Inc; and Brill Engines.
Chair:
John D. Gelles, OD, FAAO, FIAOMC, FCLSA, FSLS, FBCLA
Director, Specialty Contact Lens Division
Cornea and Laser Eye Institute
CLEI Center for Keratoconus
Assistant Clinical Professor, Department of Ophthalmology
Rutgers New Jersey Medical School
Adjunct Clinical Professor, New England College of Optometry
State University of New York College of Optometry
Illinois College of Optometry
Teaneck, NJ
Disclosures: Research/Consultant: CorneaGen, OSI, Ovitz, UltraVision; Consultant: Corza Medical, Essiri; Speaker: Glaukos, Oculus.
Faculty:
John Hovanesian, MD, FACS
President, Harvard Eye Associates
Specialist in Cornea, External Ocular Disease, Refractive and Cataract Surgery
Clinical Faculty, UCLA Jules Stein Eye Institute
Laguna Hills, CA
Disclosures: Grant/Research Support: AcuFocus, Aerie, Alcon, Allergan, Bausch + Lomb, Cord LLC, EyePoint, Glaukos, Imprimis, Johnson & Johnson Vision, Novartis, Omeros, On Point Vision, Research Insight LLC, Sight Sciences, Sun Pharma, Zeiss; Consultant: AcuFocus, Aerie, Alcon, Allergan, Apellis, Avellino Labs USA, Azura Ophthalmics, BlephEx, Bruder Healthcare, BVI, Centricity Vision, Cloudbreak Therapeutics, Cord LLC, CorneaGen, Dompe, Eyedetec, EyePoint, Glaukos, Glint Pharma, Gobiquity, GSK, Hasa Optix, Horizon Therapeutics, Hoya, Imprimis, Johnson & Johnson Vision, Kala, Novartis, Ocular Therapeutix, Oculis, Omeros, On Point Vision, Orasis, Oyster Point Pharma, Rayner, Research Insight LLC, Sensimed, SightLife, Sun Pharma, Tarsus, TearLab, Thea Pharma, Touch Ophthalmology, Trefoil Therapeutics, Vindico Medical Education, Visus, Zeiss; Other: Alcon, Alicia Surgery Center, Allegro Ophthalmics, Allergan, Apellis, Bausch + Lomb, BlephEx, Bruder Healthcare, BVI, Cloudbreak Therapeutics, Cord LLC, CorneaGen, Crisper, Dompe, Eyedetec, EyePoint, Glaukos, Glint Pharma, Gobiquity, Guardion Health Sciences, Harvard Eye Associates, Hasa Optix, Horizon Therapeutics, Hoya, Johnson & Johnson Vision, Novartis, Ocular Therapeutix, Omeros, Orasis, Research InSight LLC, RxSight, Sight Sciences, SightLife, Slack Books, Sun Pharma, Tarsus, Tear Clear, Trefoil Therapeutics, Versant Ventures and its investments, Visionary Ventures Fund 1 and 2 and its investments, Visus, Zeiss.
Faculty, Staff, and Planners’ Disclosures
In accordance with ACCME Guidelines, PER® has identified and resolved all conflicts of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.
The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies.
This podcast, including the narration, was developed by PER® editorial staff based on an online activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool.
To learn more about this topic, including information on the latest treatment strategies for patients with neurotrophic keratitis, go to https://www.gotoper.com/courses/neurotrophic-keratitis-insights-an-interactive-corneal-sensitivity-testing-workshop.
Release Date
August 30, 2025
Expiration Date
August 30, 2026
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
Episode Description
Although neurotrophic keratitis (NK) is considered a rare eye disease, it is a degenerative corneal disease that can profoundly affect patients' lives. Left untreated, NK can lead to corneal ulceration, melting, and perforation, which can ultimately lead to vision loss. In this podcast, experts Quan Dong Nguyen, MD, MSc; and Cecelia Koetting, OD, FAAO, DipABO; discuss the diagnosis, staging, and treatment of NK, focusing on early-stage disease.
Acknowledgment of Educational Grant Support
This activity is supported by an educational grant from Dompé US, Inc.
Quan Dong Nguyen, MD, MSc
Professor of Ophthalmology
Byers Eye Institute, Stanford University School of Medicine
Stanford, CA
Disclosure: Research Support: Active Biotech, Genentech, Oculis, Priovant, Regeneron; Advisory Boards: Kriya, Oculis, Priovant, Regeneron.
Cecelia Koetting, OD, FAAO, DipABO
Clinical Instructor
Department of Ophthalmology
University of Colorado School of Medicine
Denver, CO
Disclosure: Grant Support: KALA BIO, Ocular Therapeutix, Tarsus Pharmaceuticals, Viatris; Consultant: AbbVie, Alcon, Aldeyra Therapeutics, Azura Ophthalmics, Bausch + Lomb, Blinkjoy, Bruder Healthcare, Dompé US, Glaukos, Myze, Orasis Pharmaceuticals, Sight Sciences, Tarsus Pharmaceuticals, Théa Pharma, Topcon Healthcare, Twenty/Twenty, Verséa Ophthalmics, Visus Therapeutics; Speaker’s bureau: Alcon, Bausch + Lomb, Dompé US, Glaukos, Harrow, Viatris, Sight Sciences.
Faculty, Staff, and Planners’ Disclosures
In accordance with ACCME Guidelines, PER® has identified and resolved all conflict of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
This podcast was developed by PER® editorial staff based on an online activity developed with these faculty.
To learn more about this topic, including information on the diagnosis, testing, and management of patients with NK, go to https://www.gotoper.com/courses/neurotrophic-keratitis-multidisciplinary-approaches-to-enhance-patient-outcomes
Release Date
June 30, 2025
Expiration Date
June 30, 2026
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
Episode Description
In this podcast, experts Deborah Ristvedt, DO; and Melissa Tawa, OD, FAAO, discuss individualizing glaucoma therapy with selective laser trabeculoplasty and sustained-release drug implants, providing key take-home insights for optimizing glaucoma management across diverse patient profiles.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Assess non-topical therapies available for management of ocular hypertension and open angle glaucoma, including laser procedures and sustained drug delivery options
- Implement the latest advances in minimally invasive glaucoma surgery in appropriate patients
Acknowledgment of Educational Grant Support
This activity is supported by an educational grant from Glaukos Corporation and Sun Pharmaceutical Industries, Inc.
Chair
Deborah Ristvedt, DO
Anterior Segment Surgeon
Vance Thompson Vision
Alexandria, MN
Disclosures: Consultant: AbbVie, BVI Medical, Glaukos, Johnson & Johnson Surgical Vision, RxSight, Sight Sciences; Speakers Bureau: AbbVie, BVI Medical, Glaukos, Johnson & Johnson Surgical Vision, RxSight, Sight Sciences.
Faculty
Melissa Tawa, OD, FAAO
Assistant Professor
Southern California College of Optometry
Marshall B. Ketchum University
Anaheim, CA
Disclosures: Melissa Tawa, OD, FAAO, has no relevant financial relationships with ineligible companies.
Faculty, Staff, and Planners’ Disclosures
In accordance with ACCME Guidelines, PER® has identified and resolved all conflict of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.
The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies.
This podcast was developed by PER® editorial staff based on an online activity developed with these faculty.
To learn more about this topic, including information on newer mechanisms of action for topical glaucoma therapies, go to https://www.gotoper.com/courses/navigating-the-glaucoma-therapeutic-and-surgical-landscape-from-conventional-to-cutting-edge
Release Date
June 30, 2025
Expiration Date
June 30, 2026
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
Episode Description
Dry eye disease (DED) is very common among adults; however, it is often undiagnosed and untreated. As DED can have a considerable impact on a patient’s quality of life, early diagnosis and treatment are essential. In this podcast, experts Marc R. Bloomenstein, OD, FAAO; Cory J. Lappin, OD, MS, FAAO; and Selina R. McGee, OD, FAAO, discuss the roles of ophthalmologists and optometrists in managing DED in an evolving treatment landscape, from screening and diagnosis to disease management.
Acknowledgment of Educational Grant Support
This activity is supported by an educational grant from Bausch + Lomb.
Marc R. Bloomenstein, OD, FAAO
Schwartz Laser Eye Center
Scottsdale, AZ
Disclosure: Consultant: AbbVie; Allergan Aesthetics; Astellas Pharma US; Azura Ophthalmics; Bausch + Lomb; Bruder Healthcare; Dompé US; LENZ Therapeutics; Ocuphire Pharma, Inc; OCuSOFT Inc; Olleyes; Reichert Technologies; Sight Sciences, Inc; STAAR Surgical Company; Sun Pharmaceutical Industries; Tarsus Pharmaceuticals, Inc; Théa Pharma; Topcon Healthcare; Viatris Inc; Visus Therapeutics, Inc. Speaker’s bureau: AbbVie; Allergan Aesthetics; Bausch + Lomb; Dompé US; Sight Sciences, Inc; STAAR Surgical Company; Viatris Inc.
Cory J. Lappin, OD, MS, FAAO
Founder
The Dry Eye Center of Ohio
Cincinnati, OH
Disclosure: Consultant: Alcon; Barti Software; CSI Dry Eye Software; Eyenovia; Lumenis Be, Inc; MYZE; Nordic Pharma, Inc; NORWOOD Device & Diagnostics; NuLids; PRN Vision Group; Rinsada; SCOPE Health Inc; Tarsus Pharmaceuticals; Viatris Inc; Vital Tears. Speaker’s bureau: Bausch + Lomb; Bruder Healthcare; Dompé US; Lumenis Be, Inc; M&S Technologies; Other: Barti Software (Investment); MYZE (Medical Advisory Board Member/Investment); NuLids (Investment).
Selina R. McGee, OD, FAAO
Visionary Founder/Owner
BeSpoke Vision
Adjunct Faculty NSUOCO
Past-President Intrepid Eye Society
Secretary/Treasurer Oklahoma Board of Examiners
Edmond, OK
Disclosure: Consultant: AbbVie; Aldeyra Therapeutics, Inc; Alcon; Amgen, Inc; Avellino Lab USA, Inc; Bausch + Lomb; Bruder Healthcare; Carl Zeiss Meditec; Cynosure and Hahn; Dompé US; KALA BIO, Inc; Lumenis Be, Inc; Optovue; RVL Pharmaceuticals, Inc; ScienceBased Health; Sun Pharmaceutical Industries; Tarsus Pharmaceuticals, Inc; Théa Pharma; Topcon Healthcare; Versant; Viatris Inc Health. Speaker’s bureau: AbbVie; Alcon; Bausch + Lomb; Cynosure and Hahn; Dompé US; Lumenis Be, Inc; Optovue; ScienceBased Health; Sun Pharmaceutical Industries; Tarsus Pharmaceuticals, Inc; Viatris Inc.
Faculty, Staff, and Planners’ Disclosures
In accordance with ACCME Guidelines, PER® has identified and resolved all conflict of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.
The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies.
This podcast was developed by PER® editorial staff based on an online activity developed with these faculty.
To learn more about this topic, including information on the diagnosis, testing, and management of patients with dry eye disease, go to https://www.gotoper.com/courses/archived-webcast-interventional-dry-eye-a-stepwise-treatment-and-management-approach
Release Date
June 30, 2025
Expiration Date
June 30, 2026
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
Glaucoma remains a leading cause of irreversible blindness globally as progressive optic nerve damage leads to permanent vision loss. Recent advancements in glaucoma management—including novel mechanisms of action, innovative drug delivery systems, and minimally invasive glaucoma surgeries—may help improve adherence, efficacy, and outcomes.
This PER On Air Optometry Times podcast provides an in-depth review of some of the key highlights from the 18th Annual Controversies in Modern Eye Care Conference, held in May 2024. This unique and engaging multi-media activity focuses on the practical aspects of managing patients with glaucoma, putting recent clinical trial data into clinical context. The program is designed for those who did not attend the live meeting and to help reinforce learnings for those who did.
Inder Paul Singh, MD
President
The Eye Centers of Racine and Kenosha
Racine, WI
Deborah Ristvedt, DO
Anterior Segment Surgeon
Vance Thompson Vision
Alexandria, MN
Arsham Sheybani, MD
Associate Professor of Ophthalmology and Visual Sciences
Washington University School of Medicine in St Louis
St Louis, MO
Melissa Tawa, OD, FAAO
Assistant Professor
Jarnagin Center for Primary Eye Care and
Ocular Disease Service
University Eye Center at Ketchum Health
Marshall B. Ketchum University
Anaheim, CA
Jamie Parsons Malloy, OD, FAAO, associate professor at the Massachusetts College of Pharmacy and Health Sciences, and her students are currently working with CooperVision’s Give Brightly and Generation Sight programs. Both programs provide vision care solutions and resources to underserved communities.
The programs value making eye care affordable for these communities, with Malloy saying they allow for patients to receive lenses and other services who otherwise wouldn’t be able to pay for them.
“The goal really is to provide care to patients who wouldn't necessarily be able to access it, and additionally increase awareness around myopia management and its utility and its utilization within the community as well,” Malloy said.
A benefit of these programs is being able to work with new patients, especially those who are new to a certain area. Malloy says CooperVision’s Give Brightly and Generation Sight programs increase her and her students access to providing care, and gives students the opportunity to practice through fitting patients for contact lenses. On a community level, she also says the programs provides a space for patients to come in for services that may have higher rates at other practices.
Learn more about the programs here.
Jessilin Quint, OD, MBA, FAAO, chats with Optometry Times about Bausch + Lomb's State of Dry Eye survey and its key takeaways.
Experts Selina McGee, OD, Jessica Steen, OD and Laura Periman, MD, talk about some of the more common questions regarding dry eye disease and its treatment. In this program, we focus on how dry eye disease affects postmenopausal women and those patients who wear contact lenses or are candidates for refractive surgery.
This podcast provides a review of some of the key highlights from the Controversies in Modern Eye Care meeting held in April 2023. The program is designed for those who did not attend the live meeting and to help reinforce learnings for those who did.
In this episode, four expert faculty talk about the importance of early diagnosis and treatment of thyroid eye disease. They discuss the differential diagnosis, screening tests, and the need for multidisciplinary management for these patients.
Luis Rojas, OD, shares his tips and tricks for getting the best fit for multifocal contact lenses, as well as how to leverage custom fittings as a service as a marketing tool.
Danica J. Marrelli, OD, FAAO, and Alena Reznik, MD, examine the important role of co-management of glaucoma between optometrists and ophthalmologists. Expert faculty review the selection of traditional and novel topical therapies, and also patient selection for micro-incisional glaucoma surgery (MIGS).
Hear from Maria Sampalis, OD, on what to have on your checklist when purchasing a practice.
Maria Sampalis, OD, shares what she likes to look for in a practice when looking to purchase.
Jill Saxon, OD, executive director of professional strategy at Bausch + Lomb, shares the story of her career and the highlights of working within the industry.
As we near the end of this practice management series, Maria Sampalis, OD, discusses factors and indicators to watch out for when considering a practice purchase.
As we continue our conversation on practice management, Maria Sampalis, OD, gives pointers on evaluating a practice for sale and how to know if you are in a good investment spot.
In this week's podcast episode with Maria Sampalis, OD, shares how she got started with her practice's marketing.
In this week's podcast episode with Maria Sampalis, OD, hear how to differentiate between branding and marketing.
Maria Sampalis, OD, shares first steps to get started in increasing net revenue in your practice.
Continuing the conversation on practice management, Maria Sampalis, OD, shares tips on how to succeed in increasing revenue.
Continuing the conversation on practice management, Maria Sampalis, OD, shares why increasing revenue is important for a sustainable optometric practice.
In this episode of a practice management series, Maria Sampalis, OD, touches on digital platforms and the importance of utilizing them.
In this episode of a practice management series, Maria Sampalis, OD, touches on digital platforms and the importance of utilizing them.
In this episode of a practice management series with Maria Sampalis, OD, hear how to reach your target audience.
In this episode of a practice management series with Maria Sampalis, OD, learn about different online promotions and how to put them into practice.
In this episode of a practice management series with Maria Sampalis, OD, learn about the importance of social media use as a local optometrist.
In this first episode of a practice management series with Maria Sampalis, OD, learn about the importance of a brand for your optometric practice.
Vitto Mena, Jr., OD, MS, shares highlights from his VEW 2022 presentation, "My child is not old enough for contact lenses: guess again."
Vitto Mena, Jr., OD, MS, shares highlights from his VEW 2022 presentation, "Sports EYEllustrated: keep your head in the game."
Vitto Mena, Jr., OD, MS, shares highlights from his VEW 2022 presentation, "Intro to sports vision: children who play sports need safety eye protection."
Autumn is in the air—although it doesn’t feel like it at Vision Expo West in Las Vegas—and that means pumpkin spice and application time for CooperVision’s Best Practices program. Michele Andrews, vice president of professional and government affairs, shares details on what’s new with this year’s program.
Effective communication is imperative for patient adherence, it increases patient outcomes, and it reduces malpractice risks. Dr. Janette Pepper reviews how culture can act as a barrier to effective communication and what ODs can do to overcome that barrier.
Optometry Times® Editorial Advisory Board members Jeffry Gerson, OD, FAAO; and Steven Ferrucci, OD, FAAO, chat about what’s new in the retina space while at Vision Expo West 2021 in Las Vegas.
ODs can help detect visual field defects earlier with population screening, says Mohamed Abou Shousha, MD, FRCS, PhD. He is founder and CEO of Heru, which is launching its wearable field testing platform re:Vive at Vision Expo West 2021 in Las Vegas, Nevada.
Heru founder and CEO Mohamed Abou Shousha, MD, FRCS, PhD, discusses the origins behind re:Vive. The company launched the wearable visual field testing platform at Vision Expo West 2021 in Las Vegas, Nevada.
Marc Bloomenstein, OD, FAAO, and Editorial Advisory Board member for Optometry Times® outlines what attendees can anticipate from the greatest anterior segment disease and medical management of contact lens complications course ever at Vision Expo West.
Kerry Gelb, OD, talks with Gretchyn Bailey, NCLC, FAAO, about what’s coming with “Open Your Eyes.” Take a look!
Colette Carlson, professional speaker and human behavior expert, says that relationships can be transformed through the power of connected conversations. She recommends that ODs rely on stories, not data, to build trust in order to influence patients. Plus, staying “in the now” with each patient helps to keep ODs focused on the patient in front of them. Check out her conversation with Optometry Times® Editor in Chief Gretchyn M. Bailey, NCLC, FAAO.
Benjamin Gaddie, OD, FAAO, cochair of Vision Expo Meetings, outlines what attendees can anticipate about Vision Expo East 2021 in Orlando.
Alcon recently launched a multi-dose version of preservative-free lubrication drop Systane called Systane Hydration Multi-Dose Preservative-Free. Sean Clark, general manager of U.S. vision care at Alcon talks about it with Optometry Times® Editor in Chief Gretchyn M. Bailey, NCLC, FAAO.
Jimmie Johnson, 7-time NASCAR cup winner and IndyCar rookie, talks with Optometry Times® Editor in Chief Gretchyn Bailey, NCLC, FAAO, about how ocular allergies affect his driving and day-to-day life.
Johnson discusses his history of ocular allergies and what is coming next for him. Plus, he mentions his daughter’s allergies and how Alcon Pataday Once Daily Relief (olopatadine hydrochloride 0.2%) helped both of them.
Andy Pawson, president and general manager of Alcon global vision care, talks with Optometry Times® Editor in Chief Gretchyn Bailey about the company’s plan to launch a new contact lens in early 2022—Total 30 is a monthly lens incorporating water-gradient technology. Pawson discusses plans for line extensions of Total 30 to toric and multifocal lenses and comments on the status of Precision 1 for Astigmatism, which launched in late 2020.
Acuvue Theravision with Ketotifen from Johnson & Johnson Vision is the first entry into an anticipated category of drug-eluting contact lenses.
Play Video Rhett Schiffman, MD, MD, MHSA, chief medical officer and head of research and development at Visus Therapeutics, talks with Gretchyn Bailey, NCLC, FAAO, editor in chief of Optometry Times® about Brimichol, the company’s presbyopia-correcting eyedrop that recently received FDA acceptance of its investigational new drug (IND) application.
New data shows that contact lens wear is a healthy option for kids as young as age 8. Jill Woods, MSc, MCOptom, FAAO, FBCLA, discusses research summarized in a recent peer-reviewed article on the ocular health of children wearing daily disposable contact lenses. She explains the study results and offers key messages for practitioners and parents. Take a look!
Chief Optometric Editor Ben Casella, OD, FAAO, illustrates how optical coherence tomography (OCT) is a dynamic test. A Friday afternoon patient exhibited a macular smudge, and Dr. Casella performed OCT to investigate further.
Ben Casella, OD, FAAO, chief optometric editor of Optometry Times®, discusses COVID-19 vaccines and distribution with Gretchyn Bailey, editor in chief of Optometry Times®.
Rob Stutman, OD, MBA, FAAO, talks with Editor in Chief Gretchyn Bailey, NCLC, FAAO, about the upcoming World Glaucoma Week and the importance of ODs taking control of glaucoma.
Deanna Alexander, OD, chair of the Alliance for Patient Safety, discusses recent changes from the FTC on contact lenses with Chief Optometric Editor Ben Casella, OD, FAAO.
Optometry Times® Chief Optometric Editor Ben Casella, OD, FAAO, and Editor in Chief Gretchyn Bailey, NCLC, FAAO, discuss the contact lens landscape in 2020.
Darryl Glover, OD, and Howard Purcell, OD, FAAO reflect on the recent success of a new initiative to drive interest from African American students to optometry.
Consider patients’ device usage and remember to think about Dry Eye Workshop (DEWS) and DEWS II for great information on dry eye management. Read it in small bites at a time. Also, follow up with patients to make sure they’re feeling better and to ensure compliance.
Eric Donnenfeld, MD, highlights his talk from Twin Cities Ocular Surface Disease Symposium on the importance of optometry and ophthalmology working together to improve patient care, particularly with dry eye disease.
Jacob Lang, OD, FAAO, explains the interactions between glaucoma and ocular surface disease and how to approach treatment at Twin Cities Ocular Surface Disease Symposium 2019.
With the recent cancellation of the American Optometric Association's annual Optometry's Meeting, Chief Optometric Editor Ben Casella, OD, FAAO, and Editor in Chief Gretchyn Bailey, NCLC, FAAO, discuss how 2020 is progressing for ODs.
Chief Optometric Editor Ben Casella, OD, FAAO, chats with Curtis Ono, OD. Dr. Ono was recently elected as trustee for the American Optometric Association (AOA).
Brooke Messer, OD, FAAO, FSLS, shares contact lens tips for ODs and patients with dry eye and ocular surface disease at Twin Cities Ocular Surface Disease Symposium in Minneapolis.
Melanie Denton Dombrowski, OD, MBA, FAAO, offers suggestions for shooting content for YouTube. In this second installment, she addresses lighting, filming, and editing the final product.
Melanie Denton Dombrowski, OD, MBA, FAAO, outlines how ODs can get started in creating video content and creating a YouTube channel.
Yes, patients’ eyes are feeling more dry while wearing masks during the pandemic. Karen Walsh, BSc(Hons) PGDip MCOptom FIACLE, professional education team leader and clinical scientist at Centre for Ocular Research and Education (CORE) at the University of Waterloo explains mask-associated dry eye (MADE) is happening and how to prevent it. Check out https://core.uwaterloo.ca/covid-19/ for a patient-friendly infographic on MADE and other resources.
Mike McDougall, president of McDougall Communications in Rochester, NY, offers tips for medical professionals who likely have little experience with connecting with patients during trying times.
With the release of CDC guidelines on contact lens wear and publication of a peer-reviewed paper on the topic, lead author Lyndon Jones, PhD, FCAHS, FCOptom, FAAO, offers advice to ODs and patients alike about safe contact lens wear. Read the paper from Contact Lens & Anterior Eye, “The COVID-19 pandemic: Important considerations for contact lens practitioners.”
During the Dry Eye Everything meeting, Whitney Hauser, OD, suggests knowing patient objectives and outlining a treatment plan and timeline for patients so they understand what is going on.
Whitney Hauser, OD, suggests ODs take the opportunity of the COVID-19 pandemic to redirect their practices and identify new goals during the Dry EyeEverything meeting.
Melanie Denton Dombrowski, OD, FAAO, MBA, is launching a dry eye clinic and shopping for new equipment. In her research, she test drove Meibox Meibographer (Box Medical Solutions) for a few weeks. Dr. Denton weighs in on her take after a few days. She discusses pros and cons and shares several images she captured with the device.
Disclosure: Dr. Denton sits on the Bausch + Lomb speakers bureau; consults with Alcon, Optase, and Visus; and earns affiliate income from Èyes Are The Story
Editor in Chief and Content Channel Director Gretchyn M. Bailey, NCLC, FAAO, shares news updates for November 15, 2020.
The Year of Vision has not been running exactly to plan for anyone in eye care, but for Ashley Mills, the CEO of The Vision Council, it has meant a complete restructuring of eyecare’s major spring and fall Vision Expo events and the need for new innovations and outreach to help ODs navigate not just COVID-19,but topics ranging from diversity in eyecare to consumer trends in optical.
Essence Johnson, OD, FAAO, grew up in Marino Valley, CA, and upon graduating high school she was recruited to attend the historically Black universities and colleges (HBUC) Prairie View A&M University in Texas. When she got the call from the dean offering her a full scholarship to attend despite the fact she hadn’t even applied, she knew from the conversation that this was an opportunity she could not miss. That decision led to her future journey to optometry as a profession.
ODs know what they don’t know—and for most that is financial planning and tax strategies. Eric Miller, chief financial advisor for Econologics Financial Advisors, a group specializing in healthcare finances for private practice owners, talks about planning for financial success. Miller shares some of the most common mistakes he sees doctors making in their financial planning.
Ocular aesthetics injections, Irish whisky, optometric legislation, becoming a master gardener
Nutritional science, residency benefits, marketing yourself, and living on Estrogen Island
Sharing space with another OD, ODs on the front line of primary care, and Motorcycle Weekend
This month’s podcast guest Chandra Mickles, OD, MSc, FAAO, FSLS, is an associate professor at Nova Southeastern University College of Optometry and the dry eye service coordinator on campus. She is passionate about educating the next generation of optometrists about the importance of treating even the earliest stages of dry eye and exploring new technology that can improve a patient’s day to day vision and comfort experience.
Research shows that eight to 15 percent of patients with acute PVD have an associated retinal break that needs repair. However, the symptoms of flashing lights and floaters associated with acute PVD with no retinal break last on average up to three months. For some patients, however, the floater itself is a cause of significant disturbance. How can ODs help patients whose lives are disrupted by the presence of a large, persistent floater? Jessica Schiffbauer, OD, practices in an OD/MD referral clinic in Virginia Beach, VA. A day in her practice involves postoperative care, dry eye referrals, and plenty of flashes and floaters complaints.
In this podcast, Defocus Media explores what ODs need to know to position Acuvue Oasys with Transitions for success in their practices and what patient expectations to manage before getting started.
Arkansas became the fourth state to expand optometry’s scope of practice to include the use of noninvasive laser surgical procedures, including YAG capsulotomy, selective laser trabeculoplasty, and laser peripheral iridotomy. The Arkansas bill passed through House and Senate chambers with bipartisan support before being signed into law by the governor on March 27, 2019.
This month’s podcast guest is Jason Ellen, OD, who practices in an MD/OD practice in Tulsa, OK. His involvement in optometry’s political action began as a student, and he now serves as president of the Oklahoma Association of Optometric Physicians.
Unless you have been avoiding the Internet at all costs, you have likely seen an abundance of ads for new contact lens subscription services. These companies market their lenses on convenience and affordability, targeting patients directly instead of going through the normal doctor-driven prescribing and dispensing channels. We sat down with Ryan Corte, OD, who practices in the growing metropolitan city of Charlotte, NC, to learn more about why patients are increasingly interested in subscription contact lens services and how ODs can best discuss the topic with patients at their yearly eye exam.
At the end of every eye exam, Janelle Davison, OD, always asks patients if they have any other questions. She was surprised at how often the questions were related to makeup suggestions, eyelash growth, and cosmetic treatments around the eye. “Why don’t you have a place in your office to offer cosmetic services so I could get treatments done and still be under your care and supervision?” came the suggestion from a dry eye patient that she was helping to manage and find better alternatives in her cosmetic routine to reduce ocular surface irritation.
Instead of waiting to let the future happen to him, Walt Whitley, OD, FAAO, has focused on innovating and creating opportunities in his optometric career. He has made a name for himself in ocular surface disease and the opportunities for relationship-building between optometry and ophthalmology.
If you have skimmed a few summary articles and are thinking, “Dry eye not really changed much for me,” we’re highlighting the biggest takeaways from TFOS DEWS II that will make you rethink what you think you know about dry eye treatment in our podcast with Drs. Jennifer Craig, Lyndon Jones, and James Wolffsohn
If the rate of change in optometry this year has your head spinning, hold on tight with this next one. On September 18, 2017, Johnson & Johnson Vision (JJV) announced the acquisition of Sightbox, an online contact lens subscription box service that sells direct to consumer Acuvue contact lenses, and yes, contact lenses from the three other major contact lens manufacturers. It was a move that surprised many ODs, but as we look beyond the surface, this acquisition says so much about the current state of our profession and healthcare as a whole.
Find out more from J&J's Peter Menziuso.
Danielle Richardson, OD, discusses how yoga has influenced her optometric practice, patient care, and ability to balance the daily demands of optometry and being an entrepreneurial professional.
Colin Carr, founder of Carr Healthcare Realty which represents only healthcare buyers and tenants, answers the most common questions he receives from private practice optometric owners.
On this podcast, we sit down with Claudine Courey, OD, MSc, FAAO, an OD who is embracing dry eye treatment on a new stage—the world of online retail.
Early detection is key to improved outcomes for these patients born with retinoblastoma, as Dr. Bryan Shaw learned firsthand. Dr. Shaw is not an optometrist but a biochemistry professor at Baylor University. When he was completing his postdoctoral work, he got devastating news: his son was diagnosed with bilateral retinoblastoma. Once Dr. Shaw found out that he had the signs of Noah’s cancer in his own cell phone photo library four months before he was diagnosed, the light bulb went off. He decided to create an app using artificial intelligence that could help parents detect leukocoria in their own children’s photos.
Refractive surgery in 2020: From minimally invasive LASIK to light adjustable lenses with Steven Tersigni, MD.
Howard Purcell, OD, FAAO, president and CEO of the New England College of Optometry, discusses The Industry Collaborative and what it means for the profession.
Jennifer Lyerly, OD, and Darryl Glover, OD, of Defocus Media talk with Leslie O'Dell, OD, FAAO, and Amy Gallant Sullivan about Èyes are the Story, their new cosmetic line which is designed to be safe for the ocular surface.